Mon, May 5, 8:11 PM (10 days ago)
**Integra LifeSciences Holdings Corporation (IART) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $382.65 million, up 3.7% YoY. - **Net Loss:** $25.29 million, compared to $3.28 million in Q1 2024. - **Earnings per Share (EPS):** $(0.33) diluted, vs. $(0.04) in Q1 2024. - **Gross Margin:** 50.8% of revenues, down from 56.1% in Q1 2024. - **Operating Expenses:** $398.15 million, up 9.1% YoY. - **Cash Flow:** Net cash used in operations was $(11.26) million, a decrease from $15.76 million in Q1 2024. **Segment Performance:** - **Codman Specialty Surgical:** $280.66 million, up 9% YoY. - **Tissue Technologies:** $101.99 million, down 9% YoY. **Trends and Uncertainties:** - **Tariffs:** Potential adverse impact on costs and operations. - **Regulatory Issues:** Ongoing quality system remediation and FDA compliance. - **Acquisitions:** Integration of Acclarent and other strategic acquisitions. **Future Operations Impact:** - **Cost Management:** Initiatives to reduce expenses and maintain compliance. - **Product Launches:** Continued investment in new products and technologies. - **Regulatory Compliance:** Focus on addressing FDA and EU MDR requirements. **Cash Flow and Liquidity:** - **Cash and Equivalents:** $239.10 million, down from $246.38 million in Q4 2024. - **Investing Activities:** Net cash used was $(35.92) million. - **Financing Activities:** Net cash provided was $35.38 million. **Debt and Financial Covenants:** - **Compliance:** In compliance with financial covenants as of Q1 2025. - **Debt Maturity:** 2025 Notes due in August 2025, with sufficient revolving credit facility capacity. **Outlook:** - **Revenue Growth:** Expected to continue, driven by new products and acquisitions. - **Margin Improvement:** Focus on cost control and operational efficiency. - **Regulatory Environment:** Ongoing efforts to address quality system issues and compliance. **Summary:** Integra LifeSciences reported a challenging Q1 2025 with increased net loss and reduced gross margins. The company faces regulatory and tariff uncertainties but is taking steps to manage costs and maintain compliance. Strategic acquisitions and product launches are expected to drive future growth.